Blarcamesine is a sigma 1 receptor agonist which targets Alzheimer's pathology upstream of amyloid and tau pathology.

If approved, LMTX has the potential to become the first orally available disease-modifying therapy (DMT) in the UK.

Rhythm's Imcivree has shown benefit in a Phase III trial in patients with acquired hypothalamic obesity, leading to 19.8% ...

Sonnet BioTherapeutics has reported positive safety outcomes from a trial of SON-1010 with atezolizumab for solid tumours or ...

Johnson & Johnson has reported positive results from a Phase IIIb trial of Tremfya (guselkumab) for active psoriatic ...

The California Institute for Regenerative Medicine (CIRM) has given $8m to biotechnology company Tr1X to support its trial of ...

Sarepta and Roche announced a 16-year-old US patient dosed with Elevidys died of acute liver failure in March 2025.

The UK’s research and development (R&D) funding agency ARIA has granted funds to anti-clinical research organisation (CRO) ...

The Phase I trial saw repeated oral doses of ARV-102 able to more than half the protein suspected to play a factor in ...

DCTs were readily adopted during the pandemic, with many believing they were more sustainable, but experts are now ...

Compared to the IV infusion of the blockbuster cancer drug Keytruda, subcutaneous Keytruda can cut the time spent in ...

Vividion Therapeutics has dosed the first subject in a Phase I trial of an oral inhibitor, VVD-159642, aimed at treating ...